Patent US2088942A successfully refreshed from Google Patents.
Patent US6652546B1 successfully refreshed from Google Patents.
Patent US4642120A successfully refreshed from Google Patents.
US4642120A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Repair of cartilage and bones
Assignee: Ramot at Tel Aviv University Ltd
•
Filing: 1984-03-21
•
Granted: 1987-02-10
•
Expires: 2004-03-21
Abstract
Abstract There are provided compositions for repairing defects of cartilage and bones. These are provided in gel form either as such, or embedded in natural or artificial bones. The gel comprises certain types of cells. These may be committed embryonal chondocytes or any kind of mesenchyme originated cells which potentially can be converted to cartilage cells, generally by the influence of chondrogenic inducing factors, in combination with fibrinogen, antiprotease and thrombin. The cells ought to be of the species to which the composition is transplanted. It is advantageous to incorporate in the gel extracellular matrix (ECM) of chondrocytes or other hormones and/or growth factors such as SM (Somatomedin=IGF-I), FGF (fibroblast growth factor), CGF (cartilage growth factor), BDGF (bone derived growth factor) or a combination of any of these.
Inventors
- 👤 Zvi Nevo
- 👤 Samuel Itay
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 15:38
CPC Classifications
C; C12; C12N; C12N5/00; C12N5/06; C12N5/0602; C12N5/0652; C12N5/0655; A; A61; A61F; A61F2/00; A61F2/02; A61F2/30; A61F2/30756; A61K; A61K35/00; A61K35/12; A61K35/14; A61K35/32; A61K35/48; A61K35/54; A61K38/00; A61K38/16; A61K38/43; A61K38/46; A61K38/48; A61L; A61L24/00; A61L24/04; A61L24/10; A61L24/106; A61L27/00; A61L27/36; A61L27/38; A61L27/3804; A61L27/3817; C12N5/0068; A61F2/28; A61F2002/2817; A61F2310/00; A61F2310/00005; A61F2310/00359; A61L2430/00; A61L2430/02; A61L2430/06; C12N2500/00; C12N2500/30; C12N2500/38; C12N2501/00; C12N2501/70; C12N2533/00; C12N2533/50; C12N2533/56; C12N2533/90
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
61 words
A composition of the repair of defects of articular cartilage and bones by implantation, comprising: cells selected from the group consisting of embryonal chondrocytes, and mesenchyme cells of the species to which the composition is to be implanted capable of being converted by chondrogenic inducing factors to cartilage cells, and a biological glue consisting of fibrinogen, thrombin and a protease inhibitor.
Claim 2
Dependent Claim
61 words
A composition of the repair of defects of articular cartilage and bones by implantation, comprising: cells selected from the group consisting of embryonal chondrocytes, and mesenchyme cells of the species to which the composition is to be implanted capable of being converted by chondrogenic inducing factors to cartilage cells, and a biological glue consisting of fibrinogen, thrombin and a protease inhibitor.
Claim 3
Dependent Claim
17 words
The composition according to claim 1, containing from 100,000 to 500,000 chondrocytes or mesenchyme cells per milliliter.
Claim 4
Dependent Claim
18 words
The composition according to claim 1, wherein the chondrocytes comprise from 5 to 20 mg/ml extracellular matrix (ECM).
Claim 5
Dependent Claim
16 words
The composition according to claim 1, further comprising a local growth factor or a hormonal-growth factor.
Claim 6
Dependent Claim
23 words
The composition according to claim 4, wherein the local growth factor is cartilage derived growth factor (CDF) or bone derived growth factor (BDGF).
Claim 7
Dependent Claim
23 words
The composition according to claim 4, wherein the hormonal growth factor is somatomedin selected from the group consisting of serum and pituitary somatomedin.
Claim 8
Dependent Claim
37 words
The composition according to claim 1, wherein the cells are chondrocytes or cells derived from connective tissue containing undifferentiated mesenchyme trapped, cells which are capable of being induced in culture to proliferate and be converted into chondrocytes.
Claim 9
Dependent Claim
14 words
The composition of claim 1 wherein the protease inhibitor is a natural protease inhibitor.
References Cited (Backward Citations)
JPS5836545A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-02-09 | 1990-08-11 | 1991-02-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-02-09 | 1994-08-11 | 1995-02-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-02-09 | 1998-08-11 | 1999-02-10 | $7700.00 | Window Closed / Lapsed |